Abstract：Objective: To observe the clinical efficacy of Shenlingbaizhu powder combined with acupoint catgut implantation in the treatment of simple obesity patients.Methods: 128 patients with simple obesity admitted to our hospital from June 2017 to March 2020 were randomly divided into a control group and a treatment group, with 64 cases in each group. The control group was given conventional treatment, and the treatment group was given Shenlingbaizhu powder decoction combined with acupoint implantation treatment on the basis of the control group. The course of treatment was 3 months. The clinical efficacy of the two groups before and after treatment were compared, as well as body weight, body mass index (BMI), waist circumference, waist to hip ratio (WHR), waist circumference to height ratio (WHtR), body fat rate (F%), fasting blood glucose (FBG), fasting insulin ( FINS), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C),tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), white blood cells Interleukin-2 (IL-2) levels, and calculate the insulin resistance index (HOMA-IR). Results: After treatment, the total effective rate of the treatment group was significantly higher than that of the control group (P<0.05); after treatment, the scores of TCM syndromes, weight, BMI, waist circumference, WHR, WHtR, and F% of the two groups were lower than before treatment (P<0.05), and the scores of the treatment group are lower than those of the control group (P<0.05). After treatment, serum FBG, FINS, TC, TG, LDL-C, TNF-, IL-2, HOMA-IR levels were lower than before treatment in both groups (P<0.05), and the treatment group had lower records than the control group (P<0.05). After treatment, serum IL-6 and HDL-C levels in both groups were higher than before treatment (P<0.05), and the treatment group had higher records than the control group (P<0.05). Conclusion: Shenlingbaizhu powder decoction combined with acupoint catgut implantation therapy could reduce the weight of simple obese patients, improve insulin resistance, and inhibit inflammation.
王裕芳, 陈福初, 何丽欣. 参苓白术散联合穴位埋线治疗单纯性肥胖的疗效观察[J]. 河北医学, 2021, 27(4): 664-669.
WANG Yufang, CHEN Fuchu, HE Lixin. An Observation of the Effect of Shenlingbaizhu Powder Combined with Acupoint Catgut Implantation in Treating Simple Obesity. HeBei Med, 2021, 27(4): 664-669.
[1] Engin A.The Definition and prevalence of obesity and metabolic syndrome[J].Adv Exp Med Biol,2017,960(12):1~17. [2] 闫冰,庞随军.儿童肥胖的危害研究进展[J].新乡医学院学报,2018,35(9):840~842. [3] Zhou M,Wang H,Zeng X,et al.Mortality,morbidity,and risk factors in China and its provinces,1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J].The Lancet,2019,394(10204):1145~1158. [4] Apovian CM.Obesity: definition,comorbidities,causes,and burden[J].Am Manag Care,2016,22(7):176~185. [5] 宋爱群,张阳普,姚敏,等.电针对胰岛素抵抗肥胖模型大鼠脑肠肽瘦素中枢敏感性的影响[J].中医杂志,2020,61(17):1547~1552. [6] 内分泌系统疾病基层诊疗指南编写专家组.肥胖症基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(2):95~101. [7] 中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.361~364. [8] 魏玉婷,曹朝霞,李小娟,等.穴位埋线疗法的分子生物学机制研究进展[J].中华中医药杂志,2019,34(8):3633~3636. [9] 李海霞,陈楠楠.穴位埋线治疗腹型肥胖合并高脂血症临床研究[J].针灸临床杂志,2020,36(1):29~33. [10] 贾丹,吴伊恬,何訸,等.中国西南地区糖尿病前期患者中血脂异常分布及在胰岛素抵抗中的效应分析[J].四川大学学报(医学版),2018,49(4):617~619. [11] Lauterbach MA,Wunderlich FT.Macrophage function in obesity-induced inflammation and insulin resistance[J].Pflugers Arch,2017,469(34):385~396. [12] Wang T,He C.Pro-inflammatory cytokines: The link between obesity and osteoarthritis[J].Cytokine Growth Factor Rev,2018,44(11):38~50. [13] 樊佩苗,刘贺荣,宋琳,等.宁夏人群IL-6基因单核苷酸多态性对代谢综合征的影响[J].宁夏医科大学学报,2019,41(11):1122~1127.
2021, Vol. 27 
冀公网安备13080202000677号